- Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ro...

Ripretinib is Deciphera's ( DCPH ) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST. Given those result...

Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank ...